Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses

• Published in: Molecular genetics and metabolism Vol. 134; no. 3; pp. 235 - 242
• Main Authors: Aryal, Madhukar, Lau, Kelly, Boyer, Ryan, Zhou, Huiyu, Abend, Johanna, Gu, Karen, Olbertz, Joy, Gupta, Soumi, Zoog, Stephen, Larimore, Kevin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2021
• Subjects: Adult; Anti-drug antibody; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Enzyme replacement therapy; Humans; Neutralizing antibody; Palynziq; Pegvaliase; Phenylalanine - blood; Phenylalanine Ammonia-Lyase - adverse effects; Phenylalanine Ammonia-Lyase - blood; Phenylalanine Ammonia-Lyase - immunology; Phenylalanine Ammonia-Lyase - therapeutic use; Phenylketonuria; Phenylketonurias - drug therapy; PKU; Recombinant Proteins - adverse effects; Recombinant Proteins - blood; Recombinant Proteins - immunology; Recombinant Proteins - therapeutic use; Palynziq; Phenylketonuria; Anti-drug antibody; Enzyme replacement therapy; PKU; Pegvaliase; Neutralizing antibody
• ISSN: 1096-7192; 1096-7206; 1096-7206
• DOI: 10.1016/j.ymgme.2021.09.006

Pegvaliase (Palynziq®) is an enzyme substitution therapy using PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL) to reduce blood phenylalanine (Phe) levels in adults with phenylketonuria (PKU). In Phase 3 clinical studies, all subjects treated with pegvaliase developed anti-drug antibodies. To specifically evaluate pegvaliase-neutralizing antibodies (NAbs) and assess impact on pegvaliase efficacy, a novel hybrid ligand-binding/tandem mass spectrometry NAb assay was developed. Analysis of Phase 3 study samples revealed that pegvaliase NAb titers developed during early treatment (≤6 months after treatment initiation), and then plateaued and persisted in the majority of subjects during late treatment (>6 months). Subjects with the lowest/undetectable NAb titers had relatively high plasma pegvaliase concentrations and experienced the most rapid decline in blood Phe concentrations at relatively low pegvaliase dose concentrations. In contrast, subjects with higher NAb titers generally had lower plasma pegvaliase concentrations on similar low doses, with little change in blood Phe concentrations. However, with additional time on treatment and individualized dose titration, the majority of subjects achieved substantial and sustained blood Phe reduction, including those with higher NAb titers. Moreover, after maturation of the anti-pegvaliase immune response, NAb titers were stable over time and did not rise in response to dose increases; thus, subjects did not require additional dose increases to maintain reduction in blood Phe.